Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 8,345

“D-Theory of Time, or Digital Presentism, gives us a coherent picture of temporal ontology: In the absence of observers, the arrow of time doesn’t exist — there’s no cosmic flow of time. With that in mind, your timeless cosmic self resides as a hyperdimensional being outside the ordinary space-time dimensionality of your experiential self… In fact, if we are to create high fidelity first-person simulated realities that also may be part of intersubjectivity-based, multiplayer virtualities, D-Theory of Time gives us a clear-cut guiding principle for doing just that.” –Alex M. Vikoulov, The Physics of Time: D-Theory of Time & Temporal Mechanics.

This designer theme, #DTheoryofTime, is currently offered in a variety of 67 high-quality products from fancy home decor and wall art to stylish clothing, gadgetry and accessories for you to make a bold statement, to stand out from the crowd or to simply keep you excited throughout the day:

https://www.redbubble.com/shop/ap/48940097

Read more | >

Incredible Ai

Ergo Sum

Joshua Feast, CEO of Cogito, told USA Today that he sees the system as more of a coach than a replacement for human employees, who can field dozens of calls from irritated customers every day.

“I don’t think they (human customer agents) will be completely replaced,” Feast told USA Today. “Humans will always want to talk to other humans. The reason is that only other humans really understand us.”

Read more | >

The Israeli startup CorNeat Vision has received approval to conduct clinical trials of a synthetic cornea that bio-integrates with the human eye.

The Health Ministry-approved trial of the CorNeat KPro will be run at Beilinson Hospital in Petach Tikva on 10 patients suffering from corneal blindness who are either not candidates for or have experienced one or more failed cornea transplants, the company announced last week.

Follow Israel Hayom on Facebook and Twitter

Read more | >

What if Amazon moved its shipping centers downtown? Where drones fly into the buildings to pick up deliveries.

This drone beehive is one of the ideas and patents that could be part of Amazon’s city of the future.

From Amazon Go, the shop with no lines, and instant shipping and delivery, to hotels being serviced by Alexa, Amazon Echo, and Amazon Air. This mini documentary takes a look at how Amazon and Jeff Bezos are designing, and investing, into technology and new services that will bring a futuristic city to life.

Select Amazon Go footage used under Creative Commons
Life with Neil — https://youtu.be/p_uxFcza69I

Read more | >

Yesterday, Regeneron Pharmaceuticals, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), announced it was launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19. Today, it announced that it had received a $450 million contract to manufacture and supply the antibody cocktail as part of Operation Warp Speed from the Biomedical Advanced Research and Development Authority (BARDA).

BARDA is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The contract was also with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

A Phase I trial in 30 hospitalized and non-hospitalized patients with COVID-19 received a positive review from the Independent Data Monitoring Committee.

The Phase III prevention study will be run at about 100 locations and enroll about 2,000 people in the U.S. The Phase II/III treatment trials in hospitalized patients will evaluate about 1,850 hospitalized patients and 1,050 non-hospitalized patients and is planned for about 150 sites in the U.S., Brazil, Mexico, and Chile. It will study virologic and clinical endpoints. Preliminary data is expected later this summer.

The company had begun scaling up manufacturing of REGN-COV2 in the spring at its own expense. This deal with BARDA and the DoD supports continuing the manufacturing in order for it to be immediately available in the U.S. if the clinical trials are successful. That availability would be dependent on efficacy and safety and on the U.S. Food and Drug Administration (FDA)’s granting of an Emergency Use Authorization (EUA) or product approval.

Read more | >

Ow they are coming for you.

You can add giant swarms of flying ants to your 2020 scary-sounding insects Bingo card alongside murder hornets and hordes of noisy cicadas.

The UK’s Met Office shared radar imagery that showed the ants flying over the southeast part of the country.

“It’s not raining in London, Kent or Sussex, but our radar says otherwise,” it said in a tweet on Friday.

Read more | >

While the issue of aging and DNA methylation is an area that is well-studied, modifications of DNA to reduce or reverse aging remains an area in need of exploration. Studies in mice utilizing interventions such as caloric restriction and the drug rapamycin have reversed and/or slowed age-related DNA methylation by up to 40%. Understanding the cross-species aging based on similar DNA behaviors may open more doors to investigating therapeutics to minimize lifetime risks of age-related illnesses such as Alzheimer’s disease and cancers.

A recent study published in Cell Systems sought to debunk one of the most common myths about dogs: much to our surprise, one “dog year” does not equal seven “human years.” As described in a recent Forbes piece by Sara Tabin, the relationship between dog years and human years is not linear, but is based on a logarithmic formula. The research group, based at the University of California, San Diego (UCSD), created the formula as follows:

Age in human years = 16 ln(age in dog years) +31. (ln means “natural logarithm).

Read more | >